Karina Tin, Author at The Column Group

TCG Announces the Addition of TCG iPartners

TCG’s iPartners represents a new ideation advisory group comprised of leading academic investigators and biotech entrepreneurs. Working closely with TCG’s Swanson Fellows and our core investment team, this group is dedicated to crafting innovative new drug discovery company concepts, drawing on their deep scientific expertise, academic and industry networks, and entrepreneurial intuition. The iPartners consist

TCG Announces the Addition of TCG iPartners Read More »

Karina Tin

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy

Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination, Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration

Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities

TCG Announces the Addition of TCG iPartners

Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dematitis

Carmot Therapeutics expands leadership team with appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and Executive Vice President of R&D